Postnatal Cytomegalovirus Infection and the Risk of Bronchopulmonary Dysplasia
Published Date:Dec 07 2015
Source:JAMA Pediatr. 169(12):e153785.
Pubmed Central ID:PMC4699399
Funding:DPHD2075699/PHS HHS/United States
HHSN267200700051C/HD/NICHD NIH HHS/United States
K24 HD058735/HD/NICHD NIH HHS/United States
R03 HD072796/HD/NICHD NIH HHS/United States
1R18-FD005292-01/FD/FDA HHS/United States
R01AI06380/AI/NIAID NIH HHS/United States
R21 AI106494/AI/NIAID NIH HHS/United States
P30AI064518/AI/NIAID NIH HHS/United States
R01 HD081044/HD/NICHD NIH HHS/United States
DP2 HD075699/HD/NICHD NIH HHS/United States
K23 HD068497/HD/NICHD NIH HHS/United States
DP2HD2075699/DP/NCCDPHP CDC HHS/United States
1R01-HD081044-01/HD/NICHD NIH HHS/United States
HHSN275201000003I/PHS HHS/United States
UL1TR001117/TR/NCATS NIH HHS/United States
T32-HD060558/HD/NICHD NIH HHS/United States
K23HD068497/HD/NICHD NIH HHS/United States
HHSN275201000003I/HD/NICHD NIH HHS/United States
R18 FD005292/FD/FDA HHS/United States
R03HD072796/HD/NICHD NIH HHS/United States
P01 AI117915/AI/NIAID NIH HHS/United States
R01 AI106380/AI/NIAID NIH HHS/United States
UL1 TR001117/TR/NCATS NIH HHS/United States
T32 HD060558/HD/NICHD NIH HHS/United States
P30 AI064518/AI/NIAID NIH HHS/United States
R21AI0694/AI/NIAID NIH HHS/United States
HHSN272201500006C/AI/NIAID NIH HHS/United States
HHSN272201500006I/PHS HHS/United States
HHSN267200700051C/PHS HHS/United States
2K24HD058735-06/HD/NICHD NIH HHS/United States
P01-AI117915-01/AI/NIAID NIH HHS/United States
Postnatally acquired cytomegalovirus (CMV) is typically benign in term infants but, in very low birth weight (VLBW) infants, can cause pneumonitis and sepsis-like illness. Whether postnatal CMV infection results in long-term pulmonary sequelae in these infants is unknown.
To investigate the relationship between postnatal CMV infection and bronchopulmonary dysplasia (BPD) and mortality in a large, multicenter cohort of VLBW infants.
Propensity-matched retrospective cohort study.
348 neonatal intensive care units in the United States from 1997–2012.
Hospitalized VLBW (<1500 g) infants.
Postnatal CMV infection was defined as a diagnosis of CMV or detection of CMV from blood, urine, cerebrospinal fluid, or respiratory secretions on or after day of life 21. Infants with a CMV diagnosis or virologic detection of CMV prior to day of life 21 were not considered to have postnatal infection.
Main Outcomes and Measures
We matched infants with postnatal CMV infection 1:1 to comparison infants using propensity scores, and used Poisson regression to examine the effect of postnatal CMV on the combined risk of death or BPD at 36 weeks postmenstrual age. To describe features of postnatal CMV infection, we extracted clinical and laboratory data from 7 days before until 7 days after infants met criteria for postnatal CMV.
Of 101,111 infants, 328 (0.3%) had postnatal CMV infection. We matched a comparison infant to 303 (92%) CMV-infected infants for a final cohort of 606 infants. The median gestational age and birth weight of this cohort were 25 weeks and 730 g, respectively. Postnatal CMV infection was associated with an increased risk of death or BPD at 36 weeks postmenstrual age (risk ratio [RR]: 1.21, 95% confidence interval [CI]: 1.10–1.32) and BPD (RR: 1.33, 95% CI: 1.19–1.50). Changes in cardiorespiratory status associated with postnatal CMV infection included a new requirement for vasopressor medications (9%), intubation for mechanical ventilation (15%), a new oxygen requirement (28%), and death (1.2%).
Conclusions and Relevance
In VLBW infants, postnatal CMV infection was associated with increased risk of BPD. Further studies are needed to determine the role of preventative measures against CMV in this population.
application/pdf application/octet-stream image/gif image/jpeg
You May Also Like: